Clinical implications of monitoring nivolumab immunokinetics in non–small cell lung cancer patients

BACKGROUND. The PD-1–blocking antibody nivolumab persists in patients several weeks after the last infusion. However, no study has systematically evaluated the maximum duration that the antibody persists on T cells or the association between this duration and residual therapeutic efficacy or potenti...

पूर्ण विवरण

में बचाया:
ग्रंथसूची विवरण
में प्रकाशित:JCI Insight
मुख्य लेखकों: Osa, Akio, Uenami, Takeshi, Koyama, Shohei, Fujimoto, Kosuke, Okuzaki, Daisuke, Takimoto, Takayuki, Hirata, Haruhiko, Yano, Yukihiro, Yokota, Soichiro, Kinehara, Yuhei, Naito, Yujiro, Otsuka, Tomoyuki, Kanazu, Masaki, Kuroyama, Muneyoshi, Hamaguchi, Masanari, Koba, Taro, Futami, Yu, Ishijima, Mikako, Suga, Yasuhiko, Akazawa, Yuki, Machiyama, Hirotomo, Iwahori, Kota, Takamatsu, Hyota, Nagatomo, Izumi, Takeda, Yoshito, Kida, Hiroshi, Akbay, Esra A., Hammerman, Peter S., Wong, Kwok-kin, Dranoff, Glenn, Mori, Masahide, Kijima, Takashi, Kumanogoh, Atsushi
स्वरूप: Artigo
भाषा:Inglês
प्रकाशित: American Society for Clinical Investigation 2018
विषय:
Research Article
ऑनलाइन पहुंच:https://ncbi.nlm.nih.gov/pmc/articles/PMC6237460/
https://ncbi.nlm.nih.gov/pubmed/30282824
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1172/jci.insight.59125
टैग : टैग जोड़ें
कोई टैग नहीं, इस रिकॉर्ड को टैग करने वाले पहले व्यक्ति बनें!

समान संसाधन